A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 47
- 主要终点
- Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib
研究概览
简要总结
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed Stage IIIB/ IV non-small cell lung cancer (NSCLC).
- •Relapsed after treatment with 1 or 2 prior chemotherapy regimens, including at least 1 platinum-based treatment. Patients may have received pemetrexed as 1 of the prior therapies. Patients may not have received investigational therapy as their only prior therapy.
- •Recovered from the toxic effects of prior therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Smoked ≥ 100 cigarettes in their lifetime, whether a former or current cigarette smoker.
- •Adequate blood, liver and kidney function as defined by laboratory values.
- •Received 1-1.25 mg daily oral folic acid for at least 7 days prior to randomization and 1 mg intramuscular injection of vitamin B12 within 10 weeks prior to randomization.
- •Women of childbearing potential must use medically acceptable birth control and have a negative serum pregnancy test within 14 days prior to randomization. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this test.
- •Men who are not surgically sterile must use medically safe and effective birth control from the time of study randomization, and agree to continue practicing until at least 90 days after the last administration of study treatment.
- •Accessible for repeat dosing and follow-up.
- •Give written informed consent.
排除标准
- •Active concurrent primary malignancy (except non-melanoma skin cancer or in situ carcinoma of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no evidence of active or recurrent disease.
- •Use of investigational drugs, biologics, or devices within 4 weeks prior to randomization.
- •Previous exposure to pralatrexate or erlotinib.
- •Women who are pregnant or breastfeeding.
- •Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA) Functional Classification.
- •Uncontrolled hypertension.
- •Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of <100 mm3 or detectable viral load within the past 3 months, and is receiving combination anti-retroviral therapy.
- •Symptomatic central nervous system metastases or lesions for which treatment is required.
- •Major surgery within 2 weeks of study randomization.
- •Receipt of any conventional systemic chemotherapy within 4 weeks (6 weeks for nitrosoureas, mitomycin C), or radiation therapy (RT) within 2 weeks, prior to randomization.
- •Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
- •Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent or limit study compliance.
研究组 & 干预措施
Pralatrexate
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
干预措施: Pralatrexate (Drug)
Pralatrexate
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
干预措施: Vitamin B12 (Dietary Supplement)
Pralatrexate
Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
干预措施: Folic Acid (Dietary Supplement)
Erlotinib
150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
干预措施: Erlotinib (Drug)
Erlotinib
150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
干预措施: Vitamin B12 (Dietary Supplement)
Erlotinib
150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.
干预措施: Folic Acid (Dietary Supplement)
结局指标
主要结局
Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib
时间窗: Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.
OS was defined as the length of time from randomization until death due to any cause. Patients who were alive at the time of the data cut-off date were censored at the last contact date.
次要结局
- Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib(Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.)
- Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib(Assessed every 8 weeks for the first 24 weeks, then every 16 weeks for up to 2 years or until PD or start of subsequent treatment.)
- Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib(Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).)